Comparing whole body MRI with bone scans in advanced prostate cancer
Compares whole body MRI with bone scans and CT in men with advanced prostate cancer.
Plain-language title generated from the registry record
Registry title: Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone
Key facts
- Where
- Milan, ItalySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with castration-resistant prostate cancer that has spread to the bone. It compares whole body MRI with bone scans and CT scans.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Castration-resistant prostate cancer confirmed by tissue examination, with one or several bone metastases
Main reasons for not taking part
- Cannot safely have a whole body MRI, CT scan or bone scan
- Only metastatic site already treated with radical treatment (for example Cyberknife)
- Another active cancer besides prostate cancer
- Life expectancy of 6 months or less
- Personal, family, social or travel-related conditions that would make it hard to follow the study plan
Read by machine on 12 November 2026.
Where in Italy
- IEO Istituto Europeo di OncologiaMilan, ItalyContact: Giuseppe PetraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- European Institute of Oncology
- Trial code
- NCT06321679
- Record updated
- 20 March 2024
- Original description
This study is aimed to compare whole body MRI (WB-MRI) with Bone Scintigraphy (BS) and Computerized Tomography (CT) scans in patients receiving treatment for metastatic castration-resistant prostate cancer to the bone.Read full original descriptionShow less
Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) to the Bone: A Whole Body MRI Study
This study is aimed to compare whole body MRI (WB-MRI) with Bone Scintigraphy (BS) and Computerized Tomography (CT) scans in patients receiving treatment for metastatic castration-resistant prostate cancer to the bone.
This is a monocentric, prospective observational study.
Inclusion: Histological diagnosis of castration-resistant prostate cancer,; Single or multiple bone metastases,; Life expectancy of over 6 months,; No current active malignancy other than prostate cancer,; Provision of written informed consent.
Exclusion: Radical treatment of sole site of metastatic disease (e.g. Cyberknife to solitary metastatic lesion),; Psychological, familial, sociological or geographical conditions that would hamper compliance with the study protocol; such conditions are to be discussed with the patient as part of the informed consent process; Absolute contraindication to WB-MRI, CT or BS,.